Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102426 · ClinicalTrials.gov registry record · Phase 3
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
A Phase 3 study of Relapsed/Refractory Multiple Myeloma, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 3
- Development phase
- 255
- Enrollment target
- 20
- Study locations
NCT01102426: Completed Phase 3 study of Relapsed/Refractory Multiple Myeloma, sponsored by PharmaMar.
NCT01102426 is a Phase 3 study of Relapsed/Refractory Multiple Myeloma that has completed, run by PharmaMar. The registered enrollment target is 255 participants, above the 154-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01102426, a Phase 3 study of Relapsed/Refractory Multiple Myeloma, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 255 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Primary Outcome
To compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone as measured by progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Plitidepsin
Study Locations (20)
Other
- 108 - Adelaide
- 102 - Canberra
- 101 - Geelong
- 105 - Parkville
- 106 - Perth
- 104 - South Brisbane
- 109 - Woodville
- 202 - Graz
- 204 - Innsbruck
- 203 - Salzburg
- 201 - Vienna
- 205 - Vienna
- 208 - Vienna
- 304 - Bruges
- 301 - Brussels
Alabama
- 1107 - Tuscaloosa
California
- 1103 - Los Angeles
Florida
- 1105 - Jacksonville
New York
- 1102 - New York
Ohio
- 1104 - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2010-06 |
| Est. Completion | 2017-11 |
| Phase | Phase 3 |
What the finished NCT01102426 record still lists
NCT01102426 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 154-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (66% higher).
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01102426 names 20 study sites across 6 states, led by Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT01102426 about?
NCT01102426 is a clinical study titled "Aplidin - Dexamethasone in Relapsed/Refractory Myeloma". Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.
What is the current status of trial NCT01102426?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 255 participants. The study started on 2010-06. Estimated completion is 2017-11.
What conditions does trial NCT01102426 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT01102426?
The interventions under investigation include: Dexamethasone (DRUG), Plitidepsin (DRUG).
Who is sponsoring clinical trial NCT01102426?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01102426 being conducted?
This trial has 20 study locations across Alabama, California, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01102426's enrollment target sits among peer trials
255 4th of 14 higher than 11 of 14 other Relapsed/Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed/Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RECRUITING · Phase 3
-
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
COMPLETED · Phase 3
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia